Company intelligence / Profile preview

BioActs

Ownership: Private
Development stage: Commercial

Overview

BioActs has developed and commercialized fluorescent materials for optical imaging and medical diagnostics. They have received KGMP approval for their BALAMP M MRSA Detection Kit and CytoFlamma CBC Reagent for flow cytometry[1][2].

Therapeutic areas: OtherInfectious Diseases
Modalities: Fluorescent materialsdiagnostic reagents
Industry: Molecular Diagnostics

Drug pipeline

1 asset

MT-MAA hydrogel

Pre-clinical

Indications: Chronic wounds

Partnerships

NIHUCLPurdue UniversityUtah UniversityUniversity of WashingtonKorea Atomic Energy Research Institute (KAERI)

Beyond the preview

Go deeper on BioActs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioActs.

Explore the full profile